Artius Acquisition Inc. Files for $525M SPAC IPO
by Matt Cianci on 2020-06-25 at 9:06am

On Thursday morning, Artius Acquisition Inc. (AACQU) filed for a $525 million IPO. They will be focused on “technology enabled businesses that directly or indirectly offer specific technology solutions, broader technology software and services, or financial and transactional services to companies of all sizes”. Like many other SPACs, this one will likely be hunting for a “unicorn” involved in the tech space to some degree. The focus on technology is no surprise given the backgrounds of one of the co-founders, Charles Drucker.

Charles Drucker is the current CEO and Executive Chairman of Worldpay, a leading global payments company. Prior to that he led Vantiv. Both companies were acquired by Fidelity National Information Services, which SPAC investors should be familiar with. Most recently Bill Foley led Foley Trasimine, which was followed by Trebia – both SPACs include FIS board members seeking deals in the tech space. Drucker has been a part of successful traditional IPOs (Vantiv), and also led a top performing Worldpay company to eventually be acquired by FIS. Over the last eight years, he has been involved in six landmark transactions in the payments industry. Prior to his foray into payments, Drucker spent time in Fifth Third Banks’ asset management division.

The other Co-Founder, Boon Sim, is a managing partner of Artius Capital Partners, who is the sponsor focused on software and fintech investments. Prior to Artius, he spent time in the senior ranks of Temasek, a $230bn Singapore investment firm owned by the country’s government (see their portfolio holdings here). Although no longer managed by Boon Sim, the current portfolio’s holdings are mostly large cap technology and growth companies and less smaller cap or emerging technology companies. Before Temasek he served as the Global Head of M&A at Credit Suisse. Boon Sim’s deep global markets experience rounds out Charles Drucker’s extensive management experience.

Looking at this SPAC’s structure we see another 24 month, 1/3 warrant deal.  Perhaps it is the overall SPAC market momentum or the management team’s connections to other well-regarded and similar SPACs like Foley Trasimine and Trebia.  But unlike Foley Trasimene or Trebia, Artius does not have a forward purchase agreement (FPA), which puts it at a slight disadvantage to its competitors when searching for target companies. However, as with all things “SPAC” right now, selling this IPO should not pose a problem.  Look for this IPO to price mid-July.

Summary of the terms below:

 

 

Recent Posts
by Nicholas Alan Clayton on 2025-05-13 at 8:34pm

Churchill Capital Corp X (NASDAQ:CCCXU) announced the pricing of its upsized $360 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CCCXU”, Wednesday, May 14, 2025. The new SPAC aims to conduct a broad search for a business combination target leveraging its teams existing network and expertise. Churchill...

by Nicholas Alan Clayton on 2025-05-13 at 1:07pm

Jena II (NYSE:JENAU) has filed for a $200 million SPAC that brings serial SPAC leader William P. Foley II and his team back into the ring. This pedigree is clear in the terms the team has been able to command with just one right to a 1/20 share in each unit and 24 months to...

by Nicholas Alan Clayton on 2025-05-13 at 8:24am

At the SPAC of Dawn Investors are set to get an update on Core CPI inflation readings this morning as de-SPACs continue to report on operational advances alongside their first quarter earnings. Among them, eVTOL developer Archer (NYSE:ACHR) noted that it is on track to deliver its first Midnight aircraft to the UAE in the...

by Nicholas Alan Clayton on 2025-05-12 at 5:17pm

Perimeter Acquisition Corp. I (NASDAQ:PMTRU) announced the pricing of its upsized $210 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “PMTRU”, Tuesday, May 13, 2025. The new SPAC aims to combine with a target company with that can contribute to the re-industrialization of the United States economy,...

by Nicholas Alan Clayton on 2025-05-12 at 1:14pm

Horizon Space II (NASDAQ:HSPT) has signed a definitive agreement to combine with clinical stage biotech firm SL Bio Ltd. for $5.57 billion in equity consideration. Taipei, Taiwan-based SL Bio is developing drug candidates to treat several cancer types while also selling over-the-counter beauty products derived from natural extracts. The combined company is expected to trade...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved